S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in
NASDAQ:CLVS

Clovis Oncology Stock Forecast, Price & News

$7.94
-0.27 (-3.29 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.90
Now: $7.94
$9.55
50-Day Range
$4.45
MA: $5.37
$8.21
52-Week Range
$3.62
Now: $7.94
$11.63
Volume22.87 million shs
Average Volume8.12 million shs
Market Capitalization$701.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Clovis Oncology logo

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

994th out of 1,926 stocks

Pharmaceutical Preparations Industry

475th out of 772 stocks

Analyst Opinion: 2.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.01 million
Book Value($3.17) per share

Profitability

Net Income$-400,420,000.00
Net Margins-230.34%

Miscellaneous

Market Cap$701.25 million
Next Earnings Date2/22/2021 (Estimated)
OptionableOptionable
$7.94
-0.27 (-3.29 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

How has Clovis Oncology's stock price been impacted by Coronavirus?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS stock has increased by 28.7% and is now trading at $7.94.
View which stocks have been most impacted by COVID-19
.

Is Clovis Oncology a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Clovis Oncology?

Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clovis Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Clovis Oncology
.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.12. The biopharmaceutical company earned $38.77 million during the quarter, compared to analysts' expectations of $42.34 million.
View Clovis Oncology's earnings history
.

What guidance has Clovis Oncology issued on next quarter's earnings?

Clovis Oncology issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million.

What price target have analysts set for CLVS?

6 equities research analysts have issued twelve-month price objectives for Clovis Oncology's shares. Their forecasts range from $3.00 to $17.00. On average, they anticipate Clovis Oncology's share price to reach $9.20 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts' price targets for Clovis Oncology
or view Wall Street analyst' top-rated stocks.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. (0.60%), Vigilare Wealth Management (0.04%), Pacer Advisors Inc. (0.03%), Diversified Trust Co (0.02%) and GWM Advisors LLC (0.01%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology
.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., and Vigilare Wealth Management. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding.
View insider buying and selling activity for Clovis Oncology
or view top insider-selling stocks.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, Pacer Advisors Inc., and GWM Advisors LLC. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology
or or view top insider-buying stocks.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $7.94.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $701.25 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.